Gunter R. Rowson-Fingerle
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
Retraction Notice to: Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 01, 2026
TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile.
Journal: Molecular cancer therapeutics
Published: March 06, 2025
TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy.
Journal: Molecular cancer therapeutics
Published: January 21, 2025
Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancer.
Journal: Scientific reports
Published: May 23, 2023
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 22, 2021
CD74 is dispensable for development of chronic lymphocytic leukemia in Eµ-TCL1 transgenic mice.
Journal: Leukemia & lymphoma
Published: July 16, 2020
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: January 23, 2020
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.
Journal: Haematologica
Published: November 14, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Journal: American journal of hematology
Published: June 11, 2019
MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model.
Journal: The Journal of clinical investigation
Published: January 03, 2019
Last Updated: 09/26/2026